Windtree Therapeutics (WINT) Stock Price, News & Analysis

Company Overview

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.

Key Stats

• Today's Range: $0.31 to $0.33
• 50-Day Range: $0.30 to $1.07
• 52-Week Range: $0.29 to $14.75
• Volume: 686,581 shs
• Average Volume: 792,134 shs
• Market Capitalization: $2.83 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Hold

Windtree Therapeutics Stock Analysis - MarketRank™

Windtree Therapeutics scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Windtree Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Windtree Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Windtree Therapeutics are expected to grow in the coming year, from ($5.66) to ($2.86) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Windtree Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Windtree Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Windtree Therapeutics has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.56% of the float of Windtree Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Windtree Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Windtree Therapeutics has recently increased by 228.49%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Windtree Therapeutics does not currently pay a dividend.

Dividend Growth

Windtree Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.56% of the float of Windtree Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Windtree Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Windtree Therapeutics has recently increased by 228.49%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: N/A

News Sentiment

Windtree Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Windtree Therapeutics this week, compared to 1 article on an average week.

Search Interest

2 people have searched for WINT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Windtree Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,942.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 0.93% of the stock of Windtree Therapeutics is held by insiders.

Percentage Held by Institutions

Only 29.33% of the stock of Windtree Therapeutics is held by institutions.

WINT Stock Analysis - Frequently Asked Questions

How have WINT shares performed this year?

Windtree Therapeutics' stock was trading at $12.9420 at the start of the year. Since then, WINT shares have decreased by 97.6% and is now trading at $0.3150.
View the best growth stocks for 2024 here.

How were Windtree Therapeutics' earnings last quarter?

Windtree Therapeutics, Inc. (NASDAQ:WINT) announced its quarterly earnings results on Monday, August, 19th. The company reported ($20.91) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($8.11) by $12.80.

When did Windtree Therapeutics' stock split?

Windtree Therapeutics shares reverse split on Monday, April 22nd 2024. The 1-18 reverse split was announced on Monday, April 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

How do I buy shares of Windtree Therapeutics?

Shares of WINT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Windtree Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Windtree Therapeutics investors own include Plug Power (PLUG), Trevena (TRVN), SNDL (SNDL), AMC Entertainment (AMC), Sphere 3D (ANY), BioCardia (BCDA) and Sonnet BioTherapeutics (SONN).

Company Calendar

• Last Earnings: 8/19/2024
• Today: 12/26/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:WINT
• CUSIP: N/A
• CIK: 946486
• Web: www.windtreetx.com
• Phone: (215) 488-9300
• Fax: 215-488-9301
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.00
• High Stock Price Target: $7.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +2,145.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($16.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-20,290,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -362.76%
• Return on Assets: -79.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.27
• Quick Ratio: 0.27

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.17 per share
• Price / Book: 0.03

Miscellaneous

• Outstanding Shares: 8,990,000
• Free Float: 8,906,000
• Market Cap: $2.80 million
• Optionable: Not Optionable
• Beta: 0.54